KPRX
Kiora Pharmaceuticals, Inc.
There isn't enough reported data to score KPRX yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
KPRX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
KPRX's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
KPRX PE Valuation
KPRX has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
KPRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect KPRX's losses to shrink, with revenue holding steady.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
KPRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.79 | -$0.53 |
| Q2 2026 | -$2.50 | +$0.58 |
| Q1 2026 | -$2.70 | +$0.37 |
| Q4 2025 | -$2.64 | -403% |
| Q3 2022 | -$367.47 | +$183.33 |
| Q2 2022 | -$417.60 | +$187.20 |
| Q1 2022 | -$478.80 | +$136.80 |
| Q4 2021 | -$514.80 | +$122.40 |
KPRX lost $2.79 per share over the past year, a bigger loss than the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over KPRX on earnings quality, reporting a profit while its opponent remains loss making.
KPRX Quarterly Revenue
KPRX's revenue is growing: $1M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -169% | N/A |
| Q2 2024 | -12724% | N/A |
| Q1 2024 | 83% | N/A |
UNH has the edge over KPRX on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over KPRX on profitability, with a higher operating margin.
KPRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$557.9K | +$715.6K |
| Q1 2026 | -$3.2M | -$462.2K |
| Q4 2025 | -$2.3M | -$51.3K |
| Q3 2025 | -$1.3M | -238% |
| Q1 2025 | -$2.7M | -120% |
| Q4 2024 | -$2.2M | +$374K |
| Q3 2024 | $920.1K | +$3.4M |
| Q1 2024 | $13.6M | +$16.7M |
KPRX has burned cash in almost every quarter: −$8M over the past year, against −$5M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
KPRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +117K shares |
| 1 year | +44% | +1.9M shares |
| 3 years | +2940% | +6.1M shares |
| 5 years | +49822% | +6.3M shares |
KPRX has 6M diluted shares, up 44% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over KPRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
KPRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2024 | -0.8x | Net Cash |
| Q3 2024 | -1.1x | Net Cash |
| Q2 2024 | -2.5x | Net Cash |
| Q1 2024 | -12.0x | Net Cash |
KPRX has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
KPRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.6 | Oversold |
| Stochastic | 1.2 | Oversold |
KPRX's weekly RSI is 23 (oversold) and its Stochastic is 1 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
KPRX PE vs Healthcare Sector
KPRX has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
KPRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.09 | 36% below |
| 20 week MA | $2.40 | 45% below |
| 50 week MA | $2.31 | 42% below |
| 100 week MA | $2.64 | 50% below |
| 200 week MA | $6.48 | 79% below |
KPRX is in a downtrend: it's below all five of its weekly moving averages, and 79% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over KPRX on trend strength, trading above more of its moving averages.
KPRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3,351.6 | $2,138.4 | -36% |
| 2021 | $2,138.4 | $312.5 | -85% |
| 2022 | $312.5 | $22.1 | -93% |
| 2023 | $22.1 | $4.70 | -79% |
| 2024 | $4.70 | $3.29 | -30% |
| 2025 | $3.29 | $1.97 | -40% |
| 2026 YTD | $1.97 | $1.33 | -32% |
KPRX has finished every year since 2020 lower, and it's down 32% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over KPRX on returns for 2026, with the stronger performance.